Aruna Bio Announces Preclinical Results from Pilot Study Evaluating Unmodified Neural Stem Cell Exosomes (AB126) for the Treatment of Amyotrophic Lateral Sclerosis (ALS)/Lou Gehrig’s Disease

On September 7, 2023, Aruna Bio, Inc., a leader in neural-exosome-based therapeutics for the treatment of neurodegenerative diseases, announced preclinical results from a pilot study evaluating AB126 in a superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis (ALS) mouse model. SOD1-ALS is a rare, genetic form of ALS. A weekly dose of AB126, starting at the onset of ALS symptoms and extending through the study endpoint, demonstrated prolonged survival and reduced inflammation in the spinal cord compared to vehicle. AB126-treated animals also demonstrated reduced levels of neurofilament light chain levels in serum compared to vehicle-treated animals. AB126 is an unmodified neural stem cell-derived exosome with an innate ability to cross the blood brain barrier and modulate the inflammasome in the central nervous system (CNS) through the action of newly-discovered anti-inflammatory and neuroprotective mechanisms.

Login Or Register To Read Full Story